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Available online 2 October 2004Abstract—The solution behaviour of some novel organogold(III) compounds was investigated, and their cytotoxic properties
evaluated against a few human tumour cell lines (A2780/S, A2780/R, MCF7, HT29 and A549). Specifically, the following
compounds were considered: [Au(bipydmb-H)(2,6-xylidine-H)][PF6] (AuXyl) and [Au(bipy
dmb-H)(p-toluidine-H)][PF6] (AuTol)
(in which bipydmb = 6-(1,1-dimethylbenzyl)-2,2 0-bipyridine), [Au(pydmb-H)(AcO)2] (AuPyAcO) (in which py
dmb = 2-(1,1-dimeth-
ylbenzyl)-pyridine) and [Au(pzPh-H)Cl3]K (AuPzCl) (in which pz
Ph = 1-phenylpyrazole). The solution chemistry of these
compounds, under physiological-like conditions, was investigated through UV–vis absorption and 1H NMR spectroscopies. Signifi-
cant cytotoxic effects in vitro were observed in selected cases.
 2004 Elsevier Ltd. All rights reserved.1. Introduction
We have recently shown that various gold(III) com-
plexes exhibit promising cytotoxic effects in vitro and
are good candidates for further evaluation as antitu-
mour agents.1 Additional reports on the antitumour
properties of selected gold(III) complexes are the result
of the research activities of other groups.2–6 Notably,
gold(III) compounds seem to exert their growth inhibi-
tory effects through mechanisms that are distinct from
those of the classical anticancer platinum(II) com-
plexes.7 Among the recently tested compounds, the
organogold(III) complex, [Au(bipydmb-H)(OH)][PF6],
characterised by an appreciable stability within physio-
logical conditions, has proved to be very active against
the A2780 cell line;8 at variance with the platinum(II)
complexes, its biological activity seems to be unrelated
to a direct interference with DNA function and meta-
bolism.8 This prompted us to consider the solution
behaviour and the biological properties of some addi-
tional gold(III) compounds characterised by the pres-0968-0896/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
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4573385; e-mail: luigi.messori@unifi.itence of a direct carbon–gold(III) bond; we believe that
this latter feature is very important for the stabilisation
of the oxidation state +3 of the gold centre. For this pur-
pose, we took advantage of various recent studies on the
synthesis, characterisation and reactivity of gold(III)
cyclometallated derivatives.9–11
In particular, we report here on the solution chemistry
and the biological properties of four organogold(III)
compounds: [Au(bipydmb-H)(2,6-xylidine-H)][PF6]
(AuXyl) and [Au(bipydmb-H)(p-toluidine-H)][PF6]
(AuTol) (in which bipydmb = 6-(1,1-dimethylbenzyl)-
2,2 0-bipyridine),12 [(Au(pydmb-H)(AcO)2] (AuPyAcO)
(in which pydmb = 2-(1,1-dimethylbenzyl)-pyridine)12
and [Au(pzPh-H)Cl3]K (AuPzCl) (in which pz
Ph = 1-
phenylpyrazole).13 The AuXyl and AuTol compounds,
both featuring the same terdentate C, N, N ligand,
inspired us by the encouraging results recently attained
with the parent compound [Au(bipydmb-H)(OH)][PF6].
Specifically, we wanted to establish whether the intro-
duction of a bulkier ligand in the fourth coordination
position might have effects on the solution behaviour
and the pharmacological profile of this organogold(III)
compound. At variance, AuPyAcO, having a cyclo-
metallated C, N ligand, and AuPzCl, with a monoden-
tate C ligand, represent examples of compounds in
which the gold(III) centre is less protected than in the
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accessible coordination positions occupied by two
acetate groups whereas AuPzCl bears three exchange-
able chlorides that might undergo facile hydrolysis with-
in an aqueous environment.
Overall, we have observed that the organogold(III) moie-
ties of all these compounds, except AuPzCl, are gener-
ally stable under physiological conditions, and exhibit
significant cytotoxic properties towards a restricted
panel of human tumour cell lines. Based on these obser-
vations, the present compounds may be of interest for
further evaluation as anticancer agents.2. Results
2.1. Main structural aspects
The following compounds have been considered in the
present study: AuXyl, AuTol, AuPyAcO and AuPzCl
(see Scheme 1). The structure in the solid state has been
determined only for AuXyl;12 that of the analogous
compound AuTol can be deduced from spectroscopic
data and other physicochemical measurements. Equally,
the organometallic fragments of AuPzCl and AuPyAcO
are confidently assumed to match those of the related
complexes [Au(pzPh-H)(3,5-Me2py)Cl2]
13 and [Au-
(pydmb-H)Cl2],
14 respectively, whose crystal structures
have been ascertained by X-ray diffraction analysis.
Notably, all these compounds are characterised by the
presence of a direct carbon–gold bond. AuXyl and
AuTol, obtained by proton exchange of [Au(bipydmb-
H)(OH)][PF6] with 2,6-xylidine and p-toluidine, respec-
tively, show a significant enhancement of the hydropho-
bic properties compared to the parent complex.12 In
AuPyAcO the cyclometallated benzylpyridine provides
a nitrogen and a carbon donor to the square planar
gold(III) centre; the remaining coordination sites of
the square plane being occupied by two acetate ligands.
In AuPzCl the gold(III) centre is coordinated to a car-
bon atom of the 1-phenylpyrazole ligand and to three
chlorides. In all cases, the presence of the carbon–goldN
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Scheme 1. Schematic drawing of the four gold(III) complexes.bond is believed to confer sufficient redox stability to
the gold(III) centre.
2.2. Solution chemistry
The stability in solution of the various organogold(III)
compounds was assayed by simple spectrophotometric
measurements. Measurements were carried out within
different solvents (DMSO, dichloromethane, water and
the reference physiological buffer containing 50mM
sodium phosphate 100mM NaCl, pH = 7.4). Some sig-
nificant spectrophotometric results are shown in Figure 1.
AuXyl and AuTol are stable in organic solvents such as
dichloromethane or DMSO. Under these conditions
both compounds exhibit an intense band in the visible
(centred around 420nm) that is tentatively assigned as
a N to gold(III) charge transfer. The hydrolysis of both
compounds, either in water or in a physiological-like
buffer, is very fast and results into nearly complete dis-
appearance of the 420nm band; notably, hydrolysis in
water is accompanied by a significant pH decrease.
However, the UV transitions characteristic of the Aubi-
pydmb scaffold (centred at 320nm)8 are not perturbed
upon hydrolysis. The Au(bipydmb-H)(OH)]+ species is
most likely formed in both cases by proton exchange
of the amidogold complexes AuXyl and AuTol with
water; concomitant release of the aromatic amine takes
place. Indeed, these compounds can be quantitatively
obtained by the reaction of [Au(bipydmb-H)(OH)][PF6]
with an excess of the corresponding amines, only pro-
viding that water, produced by the reaction, is
removed.12
Solutions of AuPyAcO, either in water or in organic sol-
vents, are colourless. When dissolved in water or in the
reference buffer, AuPyAcO exhibits some characteristic
bands in the near UV, around 260nm that are stable
with time. Upon considering that the acetate moieties
generally behave as good leaving groups in aqueous
solutions, we may expect their hydrolysis and replace-
ment by hydroxide. Apparently, the resulting species is
stable in solution for several hours.
When dissolved within organic solvents, AuPzCl im-
parts a characteristic yellow colour to the solution. In
water, or in the reference buffer, fast fading of the colour
is observed ascribed to rapid hydrolysis of gold(III)
coordinated chlorides as in the case of the AuCl4
anion.15 The process is accompanied by a drastic decrease
in pH. However, this process may be reversed, almost
completely, by addition of excess chloride, for example,
LiCl. Notably, the UV spectrum of AuPzCl, dissolved in
the buffer, shows a slow, progressive decrease of the
main band centred at 250nm (Fig. 1, IV). The process
reaches completion within about 12h at 25 C. We inter-
pret this behaviour in terms of a progressive modifica-
tion of the hydrolysed species.
Overall, from the above reported spectrophotometric
experiments, it emerges that the first three compounds,
following quick hydrolysis of their respective labile lig-
ands, produce organogold(III)-containing species that
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Figure 1. UV–vis spectra of AuXyl (I), AuTol (II), AuPyAcO (III) and AuPzCl (IV). Traces a represent the compounds dissolved in DMSO at 5mM
concentration. Then the DMSO mother solutions of the four compounds were diluted 1:4 either in pure DMSO (traces b) or in the reference
phosphate buffer (traces c) or in water (traces d).
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ditions. At variance, the hydrolysis product of AuPzCl
manifests a lower stability and undergoes further
transformations.
The behaviour in solution of AuXyl and AuTol was fur-
ther analysed by 1H NMR spectroscopy. The spectra
were recorded either in deuterated DMSO or in deuter-
ated aqueous solutions. Notably, the 1H NMR spectra
of AuXyl and AuTol, in DMSO, exhibit the resonances
characteristic of the cyclometallated bipyridine ligand,
plus resonances assigned to the xylidine or toluidine moie-
ties coordinated to the gold(III) centre. Upon hydrolysis
within the reference deuterated buffer, the 1H NMR
spectra exhibit some characteristic modifications that
are ascribed to release of either xylidine or toluidine from
gold(III) coordination; at the same time loss of the char-
acteristic colour is detected. In the final 1H NMR spectra
signals characteristic of free xylidine or free toluidine are
easily recognised (at 6.87, 6.60 and 2.06ppm for xylidine;
at 6.97, 6.65 and 2.13ppm for toluidine) in agreement
with our hypothesis.
Thus, the 1H NMR results confirm the picture coming
out from the spectrophotometric measurements. AuXyl
and AuTol dissolved in the buffer rapidly hydrolyse
their amide ligands. However, the molecular scaffold
of these compounds, characterised by the presence of a
direct carbon-to-gold bond, is pretty stable and does
not show any sign of reduction of the gold(III) centre.
2.3. Cytotoxic effects
Owing to the appreciable stability of the various organo-
gold(III)-containing fragments under physiological-likeconditions, all the above compounds could be evaluated
in vitro as potential cytotoxic agents.
These organogold(III) compounds were tested against
the following human tumour cell lines: A2780/S,
A2780/R (ovarian cancer), MCF7 (breast cancer),
HT29 (colon cancer) and A549 (lung cancer). Their
growth inhibitory properties were analysed through the
classical sulforhodamine-B method.12 Results are shown
in Table 1. For comparison purposes, results obtained
with [Au(bipydmb-H)(OH)][PF6]—the precursor of AuXyl
and AuTol; oxaliplatin and cisplatin (both currently used
as anticancer drugs in the clinics) are also reported.
Notably, AuPyAcO and AuXyl proved to be signifi-
cantly active against the two ovarian carcinoma cell
lines, with IC50 values of 2.90 ± 0.34lM and
2.50 ± 0.43lM, respectively, on the A2780/S cell line.
Cross-resistance is relatively modest as it emerges from
inspection of the data obtained on the A2780/S and
A2780/R lines. Lower but still important cytotoxic
effects were produced by AuTol (6.15 ± 1.40lM) and
[Au(bipydmb-H)(OH)][PF6] (8.20 ± 2.0lM) on the same
A2780/S line. Modest effects were observed on the
MCF7 cell line, except for AuXyl (5.20 ± 0.40lM)
(5.30 ± 0.87lM); negligible effects were generally meas-
ured on the HT29 and A549 lines. At variance with
the other organogold(III) compounds, AuPzCl turned
out to be virtually devoid of cytotoxicity towards all
tested cell lines, probably in relation to its lower chemi-
cal stability profile.
It is worthwhile noting that the three compounds [Au-
(bipydmb-H)(OH)][PF6], [Au(bipy
dmb-H)(2,6-xylidine-
H)][PF6] and [Au(bipy
dmb-H)(p-toluidine-H)][PF6]
Table 1. IC50 (lM) values of organogold(III) compounds in human tumour cells, sensitive or resistant to cisplatin
Compounds IC50 (lM)
a
A2780/S A2780/R MCF7 HT29 A549
AuPzCl 30.20 ± 0.24 31.30 (1.0) 33.70 ± 2.15 >50 >50
[Au(bipydmb-H)(OH)][PF6] 8.20 ± 2.00 12.70 ± 1.42 (1.6) 35.30 ± 8.80 24.60 >50
AuPyAcO 2.90 ± 0.34 6.40 ± 0.10 (2.2) 17.70 ± 0.44 8.60 49
AuXyl 2.50 ± 0.43 5.70 ± 0.03 (2.3) 5.20 ± 0.40 25 35
AuTol 6.15 ± 1.40 14.30 ± 0.94 (2.3) 18.10 ± 0.64 25 35
Cisplatin 0.33 ± 0.04 6.40 ± 0.87 (19.3) 5.30 ± 0.87 6.30 ± 0.23 —
Oxaliplatin 0.40 ± 0.12 0.20 ± 0.02 (0.5) 0.13 ± 0.10 0.40 ± 0.16 —
Data were collected after 72h exposure to the drugs.
a IC50 is defined as the concentration of drug required to inhibit cell growth by 50% compared to control; it is expressed as mean ± SE of at least three
determinations or mean of two determinations; values in parentheses ( ) denote the ratios of IC50 of cisplatin-resistant cell line and IC50 of parental
sensitive cell line.
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against the tested cell lines, in spite of the fact that all of
them most likely transform into the same species when
dissolved in the reference buffer. This observation
implies that the presence of the 2,6-Me2C6H3NH
 or
4-MeC6H5NH
 ligand affects somehow the biological
activities of the common organogold(III) centre.3. Discussion
Owing to the encouraging in vitro antitumour properties
recently observed for Au(bipydmb-H)(OH)][PF6], new
organogold(III) complexes were prepared, characterised
and tested as potential cytotoxic agents. The solution
behaviour and the stability within a physiological-like
environment of these novel organogold(III) compounds
was investigated. In all cases, the gold(III) centre does
not undergo reduction, being adequately stabilised by
the direct carbon-to-gold bond. However, important
hydrolysis processes take place. Specifically, in the case
of AuXyl and AuTol, hydrolysis and release of either
xylidine or toluidine are clearly observed resulting in
the formation of the parent hydroxo-complex. Both
AuPyAcO and AuPzCl undergo to some extent hydroly-
sis of the anionic coligands. Afterwards, further degra-
dation is observed in the case of the pyrazolato
derivative, which bears a monodentate C ligand.
The cytotoxic properties of all these compounds were
tested against the A2780/S, A2780/R, MCF7, HT29 and
A549 human tumour cell lines. Notably, the investigated
organogold(III) compounds, with the exception of
AuPzCl, proved significantly active against the former
tumour cell lines, with cytotoxicity values falling in the
low micromolar range. Some differences were observed
in the activity patterns of AuXyl and AuTol compared
to the reference [Au(bipydmb-H)(OH)][PF6] compound.
7
Moderate effects were observed on the MCF7 and
HT29 lines, whereas negligible effects were measured on
the A549 line. Overall, similar trends of biological activity
were identified among the three active compounds that
are suggestive of a similar mechanism of action. We
believe that the specificity of their biological effects may
be ascribed to the presence of a gold(III) centre, character-
ised by an acceptable stability profile under physiologi-cal-like conditions. In the light of these observations,
the gold(III) containing molecular fragment is very
likely to be responsible for the observed cytotoxic
effects, although the actual mechanism is not yet under-
stood.4. Experimental
4.1. Chemicals
Common chemical reagents were purchased from SIG-
MA Chemical Co. (Milano, Italy) and Pharmacia. Fetal
calf serum (FCS), antibiotics, and RPMI-1640 medium
were obtained from Gibco Life Technologies Italia
(Milano, Italy).
Synthesis of [Au(bipydmb-H)(2,6-xylidine-H)][PF6]
(AuXyl),12 [Au(bipydmb-H)(p-toluidine-H)][PF6] (Au-
Tol),12 [Au(pydmb-H)(CH3 COO)2] (AuPyAcO)
12 and
[Au(pzPh-H)Cl3]K (AuPzCl).
13 The title compound was
prepared according to Refs. 12 and 13.
4.2. Electronic spectra
The absorption spectra in the UV–vis region were
recorded on a Perkin–Elmer Lambda 20 Bio spectropho-
tometer operating at room temperature. The electronic
spectra were recorded at room temperature, adding
small amounts of freshly prepared, concentrated solu-
tions of the individual complexes in DMSO to, respec-
tively, DMSO, water or to the reference buffer (50mM
phosphate, pH7.4, 100mM NaCl); the concentrations
of each gold(III) compound was 1.25 · 104. The
hydrolysis experiments were carried out monitoring
the electronic spectra of 5 · 104M gold(III) complexes
solutions in DMSO over 24h.
4.3. 1H NMR studies
Solution 1H NMR spectra of the gold(III) complexes
were recorded on a Varian Gemini 2000 spectrometer
operating at 300MHz. The 2.5 · 103M solutions were
prepared in d6-DMSO and in 50mM PO34 , 4mM NaCl,
pH7.4 deuterated buffer. The spectra were recorded
immediately after dissolution.
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Cytotoxicity studies were carried out on the A2780/S,
A2780/R, MCF7, HT29 and A549 human tumour cell
lines. The cisplatin-resistant A2780/R cell line was pro-
duced by repeated 1h weekly exposure to 50lM of the
sensitive parental cell line.8 Cell lines were cultured in
RPMI-1640 medium (GIBCO Life technologies Product
catalog, RPMI 1640 medium, Cat. no 11817) supple-
mented with 10% FCS and antibiotics (streptomycin
100lg/mL and penicillin 100U/mL) at 37 C in a 5%
CO2 atmosphere and subcultured twice weekly. Experi-
ments were conducted on exponentially growing cells.
Drugs were dissolved in DMSO. Inhibition of cell
growth was determined after a 72h drug exposure
through the Sulforhodamine-B (SRB) assay16 for the
ovarian carcinoma cell lines.References and notes
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